Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor wi... Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. 詳細を表示
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0794 | -4.07179487179 | 1.95 | 2.59 | 1.78 | 572363 | 2.17259776 | CS |
4 | 0.2806 | 17.6477987421 | 1.59 | 2.59 | 1.59 | 347165 | 1.95395889 | CS |
12 | -2.4094 | -56.2943925234 | 4.28 | 4.318 | 1.38 | 1443119 | 2.3283465 | CS |
26 | -2.6694 | -58.7973568282 | 4.54 | 4.89 | 1.38 | 682239 | 2.39252613 | CS |
52 | -5.9294 | -76.0179487179 | 7.8 | 22.35 | 1.38 | 1286031 | 8.77210518 | CS |
156 | -1033.1294 | -99.8192657005 | 1035 | 1215 | 1.38 | 1932794 | 126.93766026 | CS |
260 | -6748.1294 | -99.9722874074 | 6750 | 8182.5 | 1.38 | 1687714 | 333.85451412 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約